Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | dihydropteridine reductase | 0.0092 | 0 | 0.5 |
Entamoeba histolytica | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0092 | 0 | 0.5 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0092 | 0 | 0.5 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.1352 | 1 | 1 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0092 | 0 | 0.5 |
Leishmania major | oxidoreductase-like protein | 0.0092 | 0 | 0.5 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0092 | 0 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.1352 | 1 | 0.5 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0092 | 0 | 0.5 |
Leishmania major | pteridine reductase 1 | 0.0092 | 0 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.1352 | 1 | 1 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.1352 | 1 | 1 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.1352 | 1 | 1 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.1352 | 1 | 1 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.1352 | 1 | 1 |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0092 | 0 | 0.5 |
Loa Loa (eye worm) | oxidoreductase | 0.0092 | 0 | 0.5 |
Loa Loa (eye worm) | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0092 | 0 | 0.5 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0092 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0092 | 0 | 0.5 |
Loa Loa (eye worm) | retinol dehydrogenase 12 | 0.0092 | 0 | 0.5 |
Trypanosoma brucei | beta-ketoacyl-ACP reductase | 0.0092 | 0 | 0.5 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0092 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.1352 | 1 | 1 |
Echinococcus multilocularis | 3 oxoacyl acyl carrier protein reductase | 0.0092 | 0 | 0.5 |
Onchocerca volvulus | 0.0092 | 0 | 0.5 | |
Trypanosoma brucei | pteridine reductase 1 | 0.0092 | 0 | 0.5 |
Leishmania major | 3-oxoacyl-ACP reductase, putative | 0.0092 | 0 | 0.5 |
Schistosoma mansoni | 3-oxoacyl-[ACP] reductase | 0.0092 | 0 | 0.5 |
Onchocerca volvulus | 0.0092 | 0 | 0.5 | |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0092 | 0 | 0.5 |
Echinococcus granulosus | 3 oxoacyl acyl carrier protein reductase | 0.0092 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.8199 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.